Description
Impavido is primarily used for the treatment of leishmaniasis and visceral leishmaniasis, not colorectal cancer; there are no FDA-approved indications for its use in oncology. Preclinical studies suggest potential antitumor activity but it has not been established as a standard therapy for CCR.
Mechanism of Action
Miltefosine, the active ingredient in Impavido, inhibits phospholipid biosynthesis and disrupts cellular membrane integrity in parasitic organisms; it is not commonly used for cancer treatment but has shown some activity against certain cancers in preclinical models.
Side Effects
Nausea
Vomiting
Abdominal pain
Diarrhea; hepatotoxicity has been reported
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT03980704
med_phase_prefix4
Archived
Preoperative High Protein vs Immunodiet in Surgical Cancer Patients
Poland